Malignant high-grade osteosarcoma subtypes (conventional: osteoblastic, chondroblastic, fibroblastic, giant cell rich, osteoblastom-like, epithelioid, clear cell, chondroblastom-like
Conditions
Interventions
Group 1: When taking part patient information about tumor presentation, tumor characteristics, diagnosis and clinical follow-up will be collected by using eCRFs (Case Report Forms) and sent to the COS
Sponsors
Klinikum der Landeshauptstadt Stuttgart gKAöRZentrum für Kinder-, Jugend- und Frauenmedizin Standort Mitte (Olgahospital) Pädiatrie 5 (Onkologie, Hämatologie, Immunologie)Cooperative Osteosarkom Studiengruppe (COSS)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - All patients regardless of gender, age, tumor stage, current or future clinical trial participation with histologically proven diagnosis of one of the following tumors: Malignant high-grade osteosarcoma subtypes (conventional: osteoblastic, chondroblastic, fibroblastic, giant cell rich, osteoblastom-like, epithelioid, clear cell, chondroblastom-like; non-conventional: telangiectatic, small cell, high-grade surface), periosteal, parosteal, extra-skeletal, low-grade central, undifferentiated pleomorphic sarcoma, osseous leiomysarcoma, osseous dedifferentiated chondrosarcoma, osseous mesenchymal chondrosarcoma, osseous fibrosarcoma, osseous angiosarcoma - Obtained informed consent of the patient and/or his/her legal guardian(s)
Exclusion criteria
Exclusion criteria: - No information and informed consent of the patient and/or the legal guardian
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aims of the registry are the collection of clinical and epidemiologic data. | — |
Secondary
| Measure | Time frame |
|---|---|
| /Overall-Survival | — |
Countries
Germany
Outcome results
None listed